| Liberati, Anna Marina |
| Active, not recruiting | 3 | 128 | Europe | R2-MANT, Rituximab and Lenalidomide (R2), R-MANT, Rituximab (R) | Fondazione Italiana Linfomi - ETS | Lymphoma, Follicular | 01/23 | 08/27 | | |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
KRdvsRd, NCT04096066: A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant |
|
|
| Active, not recruiting | 3 | 84 | Europe | Carfilzomib, Kyprolis, Lenalidomide, Revlimid, Dexamethasone | Fondazione EMN Italy Onlus | Multiple Myeloma, New Diagnosis Tumor | 01/26 | 01/26 | | |
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 01/25 | 05/26 | | |
| Recruiting | 3 | 430 | Europe | Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses | Fondazione Italiana Linfomi ONLUS, GRADE Onlus | Diffuse Large B-Cell Lymphoma, Elderly Patients | 09/25 | 09/30 | | |
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma |
|
|
| Recruiting | 3 | 602 | Europe | Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B) | Fondazione Italiana Linfomi - ETS | Follicular Lymphoma | 07/28 | 07/30 | | |
FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi |
|
|
| Recruiting | 3 | 190 | Europe | Radiotherapy, Radiotherapy plus Obinutuzumab | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Follicular Lymphoma | 04/31 | 04/31 | | |
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance |
|
|
| Active, not recruiting | 2 | 75 | Europe | Ibrutinib, IMBRUVICA (commercial name) | Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A. | DLBCL | 07/24 | 07/27 | | |
| Terminated | 2 | 37 | Europe | Copanlisib, ALIQOPA | Fondazione Italiana Linfomi - ETS | Diffuse Large B-cell Lymphoma | 12/24 | 12/24 | | |
| Recruiting | 2 | 208 | Europe, RoW | Rituximab, Methotrexate, Procarbazine, Lenalidomide, Radiotherapy, Temozolomide | International Extranodal Lymphoma Study Group (IELSG) | Primary Central Nervous System Lymphoma | 12/24 | 12/24 | | |
| Recruiting | 2 | 28 | Europe | Daratumumab, Daratumumab sc, Bortezomib, Bortezomib sc, Dexamethasone, Dexamethasone os | Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A. | Plasmablastic Lymphoma | 01/25 | 01/25 | | |
| Recruiting | 1/2 | 122 | Europe | Atezolizumab, BEGEV, Bendamustine, Gemcitabine, Vinorelbine | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Relapsed or Refractory Hodgkin's Lymphoma | 04/27 | 04/30 | | |
| Recruiting | N/A | 10000 | Europe | | Fondazione Italiana Sindromi Mielodisplastiche-ETS | Myelodysplastic-Myeloproliferative Diseases | 06/16 | 05/32 | | |
CML1012, NCT01752062: Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors |
|
|
| Recruiting | N/A | 148 | Europe | | Gruppo Italiano Malattie EMatologiche dell'Adulto | Chronic Myeloid Leukemia, Pregnancy | 12/22 | 12/22 | | |
NCT03964480: Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. |
|
|
| Recruiting | N/A | 1000 | Europe, US, RoW | | Associazione Angela Serra per la ricerca sul cancro | Peripheral T-Cell Lymphoma | 01/23 | 07/25 | | |
GIMEMA, NCT04282811: Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy |
|
|
| Recruiting | N/A | 321 | Europe | Venetoclax | Gruppo Italiano Malattie EMatologiche dell'Adulto | Chronic Lymphocytic Leukemia, Relapse Leukemia, Refractory Leukemia | 01/23 | 10/25 | | |
| Recruiting | N/A | 350 | Europe | | International Extranodal Lymphoma Study Group (IELSG) | Marginal Zone Lymphoma | 12/25 | 12/25 | | |
NCT05819528: Primary Cardiac Lymphoma: Italian Multicenter Experience |
|
|
| Recruiting | N/A | 43 | Europe | | Fondazione Italiana Linfomi - ETS | Primary Cardiac Lymphoma | 04/26 | 06/26 | | |
| Recruiting | N/A | 1900 | Europe | Observation | Fondazione EMN Italy Onlus | Multiple Myeloma | 03/24 | 03/24 | | |
CLARITY, NCT03190525: Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | N/A | 520 | Europe | Quality of life questionnaires | Gruppo Italiano Malattie EMatologiche dell'Adulto | Multiple Myeloma | 12/24 | 12/24 | | |
NCT03552003: Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis |
|
|
| Recruiting | N/A | 400 | Europe | Treatment for clinical practise | Fondazione Italiana Linfomi ONLUS | Classical Hodgkin Lymphoma | 01/26 | 01/26 | | |
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice |
|
|
| Recruiting | N/A | 1500 | Europe | "novel" MAB (alone or in combination) | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Non-Hodgkin Lymphoma, B-cell | 10/38 | 10/38 | | |
| Forghieri, Fabio |
| Recruiting | 2 | 208 | Europe, RoW | Rituximab, Methotrexate, Procarbazine, Lenalidomide, Radiotherapy, Temozolomide | International Extranodal Lymphoma Study Group (IELSG) | Primary Central Nervous System Lymphoma | 12/24 | 12/24 | | |
